Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14810258 | 0.90 | CHRM1 (0.76) | GAAALDH1A1SMN1; SMN2CHRM1NPC1 | |
| SCHEMBL9214032 | 0.89 | GAA (0.62) | GAAALDH1A1SMN1; SMN2CHRM1NPC1 | |
| SCHEMBL11578382 | 0.87 | GAA (0.56) | GAAALDH1A1SMN1; SMN2CHRM1NPC1 | |
| SCHEMBL28118094 | 0.86 | GAA (0.73) | GAAALDH1A1SMN1; SMN2CHRM1L3MBTL1 | |
| SCHEMBL14964905 | 0.85 | CHRM1 (0.68) | GAAALDH1A1SMN1; SMN2CHRM1NPC1 | |
| SCHEMBL1720494 | 0.85 | MAPT (0.72) | GAAALDH1A1CHRM1L3MBTL1THRB | |
| SCHEMBL12436957 | 0.85 | GAA (0.71) | GAAALDH1A1SMN1; SMN2CHRM1L3MBTL1 | |
| SCHEMBL355693 | 0.84 | SMN1; SMN2 (0.58) | GAAALDH1A1SMN1; SMN2CHRM1NPC1 | |
| SCHEMBL3629079 | 0.84 | GAA (0.70) | GAAALDH1A1SMN1; SMN2CHRM1L3MBTL1 | |
| SCHEMBL3346477 | 0.83 | SMN1; SMN2 (0.58) | GAAALDH1A1SMN1; SMN2CHRM1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103214457-A | Azole antifungal compound and preparation method and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2013-07-24 | — | — | CN | claimed |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-03-06 | — | — | US | disclosed |
| US-20250042914-A1 | PIKFYVE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4410795-A1 | PIKFYVE KINASE INHIBITOR | Hanmi Pharm. Co., Ltd. (KR) | 2024-08-07 | — | — | EP | disclosed |
| CN-118019744-A | PIKfyve kinase inhibitors | 韩美药品株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-20240084067-A1 | NOVEL CURABLE COMPOSITION CONTAINING CYCLIC MONOMER | TOKUYAMA CORPORATION (JP) | 2024-03-14 | — | — | US | disclosed |
| EP-4286435-A1 | NOVEL CURABLE COMPOSITION CONTAINING CYCLIC MONOMER | Tokuyama Corporation (JP) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023055181-A1 | PIKFYVE KINASE INHIBITOR | 한미약품 주식회사 | 2023-04-06 | — | — | WO | disclosed |
| WO-2022163765-A1 | NOVEL CURABLE COMPOSITION CONTAINING CYCLIC MONOMER | 株式会社トクヤマ | 2022-08-04 | — | — | WO | disclosed |
| CN-103214457-B | Azole antifungal compound and preparation method and application thereof | THE SECOND MILITARY MEDICAL UNIVERSITY (CN) | 2015-08-26 | — | — | CN | disclosed |
| US-5663200-A | CARBAMOYL PEPTIDE DERIVATIVES AS VIRICIDES | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0542671-B1 | Substituted hydroquinone derivatives as intermediates of benzofuran derivatives | CIBA GEIGY AG (CH) | 1997-01-02 | — | — | EP | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |
| CN-1089253-A | The hydroquinone derivatives that replaces | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | CN | disclosed |
| US-5290939-A | Process for the manufacture of brofaromine and analogs thereof | CIBA-GEIGY CORPORATION (US) | 1994-03-01 | — | — | US | disclosed |
| EP-0542671-A1 | Substituted hydroquinone derivatives as intermediates of benzofuran derivatives | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| EP-0000167-A1 | 1,2,3,6-Tetrahydroisonicotinic acid and derivatives thereof, methods and starting products for their preparation, and pharmaceutical compositions containing them. | Krogsgaard-Larsen, Povl (DK) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042914-A1 | PIKFYVE KINASE INHIBITOR | PIKFYVE, PIP4K2B, PIP4K2C | GAA 1842/4885ALDH1A1 4861/4885SMN1; SMN2 3220/4885 |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | GAA 4330/4885ALDH1A1 1253/4885SMN1; SMN2 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.